CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Geriatric patients with CKD are at high risk for morbidity and mortality from the potential side effects of treatments.
Children on dialysis who have anemia and require high doses of drugs to treat it are at increased risk of dying prematurely.
In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.
Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.
Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.
Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.
Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.
Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
Platelets may aggregate more easily in iron-deficient patients.
Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.
In a study, ferumoxytol and iron sucrose treatment was associated with comparable increases in hemoglobin levels and adverse event rates.
This trait in African-American hemodialysis patients was associated with a 13.2% higher dose of erythropoiesis-stimulating agents.
Decreasing TSAT and higher ESA doses are associated with increasing platelet counts.
Folic acid treatment significantly improved hemoglobin levels and decreased epoetin alfa use.
Elemental iron requirement was reduced by half in patients receiving ferric citrate versus an active control.
These include use of lower ESA doses and hemoglobin levels.
